Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol.
Wang S, Li W, Hui H, Tiwari SK, Zhang Q, Croker BA, Rawlings S, Smith D, Carlin AF, Rana TM. · 2020
Read Cholesterol 25-Hydroxylase inhibits SARS-CoV-2 and other coronaviruses by depleting membrane cholesterol. by Wang S, Li W, Hui H, Tiwari SK, Zhang Q, Croker BA, Rawlings S, Smith D, Carlin AF, Rana TM. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7537045.txt.
Introduction
Wang and co-authors show that an enzyme called CH25H can block coronaviruses. The enzyme is switched on by interferon during infection. It converts cholesterol into 25-hydrocholesterol, called 25HC.
The team found CH25H induced by SARS-CoV-2 in cells. Levels also rose in patients with COVID-19. The product 25HC blocked membrane fusion by viruses. It stopped infection in lung epithelial cells. It also blocked viral entry in human lung organoids. The mechanism drains accessible cholesterol from cell membranes. That loss stops virus and cell fusion. The authors propose 25HC as a broad treatment candidate.
Catalog record
| CREATOR | Wang S, Li W, Hui H, Tiwari SK, Zhang Q, Croker BA, Rawlings S, Smith D, Carlin AF, Rana TM. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 66 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Cholesterol 25‐Hydroxylase inhibits SARS‐CoV‐2 and other coronaviruses by depleting membrane cholesterol By Shaobo Wang, Wanyu Li, Hui Hui, Shashi Kant Tiwari, Qiong Zhang, Ben A Croker, Stephen Rawlings, Davey Smith, Aaron F Carlin, Tariq M Rana Published in: The EMBO Journal DOI: 10.15252/embj.2020106057 ABSTRACT Abstract Coronavirus disease 2019 (COVID‐19) is caused by SARS‐CoV‐2 and has spread across the globe. SARS‐CoV‐2 is a highly infectious virus with no vaccine or antiviral therapy available to control the pandemic; therefore, it is crucial to understand the mechanisms of viral pathogenesis and the host immune responses to SARS‐CoV‐2. SARS‐CoV‐2 is a new member of the betacoronavirus genus like other closely related viruses including SARS‐CoV and Middle East respiratory syndrome coronavirus (MERS‐CoV). Both SARS‐CoV and MERS‐CoV have caused serious outbreaks and epidemics in the past eighteen years. Here, we report that one of the interferon‐stimulated genes (ISGs), cholesterol 25‐hydroxylase (CH25H), is induced by SARS‐CoV‐2 infection in vitro and in COVID‐19‐infected patients. CH25H converts cholesterol to 25‐hydrocholesterol (25HC) and 25HC shows broad anti‐coronavirus activity by blocking membrane fusion. Furthermore, 25HC inhibits USA‐WA1/2020 SARS‐CoV‐2 infection in lung epithelial cells and viral entry in human lung organoids. Mechanistically, 25HC inhibits viral membrane fusion by activating the ER‐localized acyl‐CoA:cholesterol acyltransferase (ACAT) which leads to the depletion of accessible cholesterol from the plasma membrane. Altogether, our results shed light on a potentially broad antiviral mechanism by 25HC through depleting accessible cholesterol on the plasma membrane to suppress virus–cell fusion. Since 25HC is a natural product with no known toxicity at effective concentrations, it provides a potential therapeutic candidate for COVID‐19 and emerging viral diseases in the future. Keywords: cholesterol 25‐hydroxylase, COVID‐19 treatment, innate immunity, restriction factor of coronaviruses, viral fusion Subject Categories: Membrane & Intracellular Transport; Microbiology, Virology & Host Pathogen Interaction INTRODUCTION Coronavirus disease 2019 (COVID‐19) is a transmissible respiratory disease caused by a novel severe acute respiratory syndrome coronavirus SARS‐CoV‐2. Since its emergence in December 2019, COVID‐19 has rapidly spread worldwide spanning 216 countries (Sun et al, 2020). As of September 7th, there are 27,236,916 confirmed cases and 891,031 deaths (WHO COVID Pandemic). There is currently no approved vaccine for this disease, and there is an urgent need for developing therapeutic strategies. The etiologic agent of COVID‐19, SARS‐CoV‐2, is an enveloped positive‐sense single‐stranded RNA virus. SARS‐CoV‐2 is a new member of the betacoronavirus genus and other closely related viruses include SARS‐CoV and Middle East respiratory syndrome coronavirus (MERS‐CoV). Both SARS‐CoV and MERS‐CoV caused serious outbreaks and epidemics in the past eighteen years (Cui et al, 2019). SARS‐CoV‐2 uses angiotensin‐converting enzyme 2 (ACE2) as a host cell receptor, and transmembrane protease, serine 2 (TMPRSS2) to cleave its spike (S) protein for entry into the cell (Hoffmann et al, 2020b). Interferons (IFNs) are induced upon coronavirus infections (Park & Iwasaki, 2020). IFNs are signaling molecules of the innate immune system that confer a first line of antiviral defense (Liu et al, 2013). Upon sensing of molecular patterns associated with viral infections, IFN pathways become activated, engendering further activation of hundreds of interferon‐stimulated genes (ISGs) that counteract many steps in the virus life cycle (Liu et al, 2013). Human type I IFNs including IFN‐α and IFN‐β function through the ubiquitously expressed type I interferon receptor (IFNAR), while type III IFNs, IFN‐λ, bind to the epithelia‐restricted type III interferon receptor (IFNLR; de Weerd & Nguyen, 2012). In vitro and clinical studies have shown that SARS‐CoV‐2 is sensitive to type I IFNs and that type I IFN treatment could be a promising therapeutic strategy for COVID‐19 (Mantlo et al, 2020; preprint: Meng et al, 2020; preprint: Zhou et al, 2020). Cholesterol‐25‐hydroxylase (CH25H) is one of the ISGs (Schneider et al, 2014), which encodes an enzyme that synthesizes the oxysterol 25‐hydroxycholesterol (25HC) from cholesterol (Lund et al, 1998). 25HC has been shown to have broad antiviral activity by inhibiting the host cell entry of human immunodeficiency virus (HIV), vesicular stomatitis virus (VSV), Zika virus (ZIKV), Ebola virus (EBOV), Nipah virus (NiV), Russian spring‐summer encephalitis virus (RSSEV), porcine viruses (PEDV, PEGV, porcine intestine coronavirus), reovirus, and norovirus (Liu et al, 2013; Li et al, 2017). For ZIKV, treatment with 25HC protected mice and rhesus monkeys from ZIKV infection (Li et al, 2017). For the mechanism of entry inhibition, there is evidence that 25HC could modify plasma membrane composition (Liu et al, 2013). However, the pathways mediating 25HC‐induced modification of the plasma membrane that inhibits virus entry are unclear. In this paper, we report the antiviral activity of CH25H against SARS‐CoV‐2 entry into human lung epithelial cells and show that 25HC broadly inhibits infection by human coronaviruses including SARS‐CoV and MERS‐CoV. By addressing the mechanism of 25HC function, we provide evidence that 25HC induced depletion of cholesterol on the plasma membrane through activating acyl‐CoA:cholesterol acyltransferase (ACAT), thereby restricting virus fusion at the cell surface. We further confirmed the inhibitory effect of 25HC on authentic SARS‐CoV‐2 infection of lung epithelial cells and viral entry in human lung organoids. These results shed light on one of the mechanisms by which interferon signaling and type I interferon therapy in COVID‐19‐infected patients counteract SARS‐CoV‐2 at the molecular level, with implications for cholesterol homeostasis in broad‐spectrum antiviral immunity. RESULTS CH25H is induced by SARS‐CoV‐2 infection and restricts viral entry Since CH25H is an ISG and broadly inhibits viruses (Liu et al, 2013), we sought to investigate the role of CH25H during SARS‐CoV‐2 infection. We analyzed RNA‐seq data of SARS‐CoV‐2 infection in two lung epithelial cell lines, Calu‐3 and A549‐ACE2 (Blanco‐Melo et al, 2020), for up‐regulated ISGs. SARS‐CoV‐2 infection dramatically induced type I and III interferons, including IFNB1 and IFNL1, but not type II interferon (Fig 1A). Multiple well‐known ISGs were simultaneously elevated, such as ISG15, OASL, IFITMs, and the IFITs (Fig 1A). Importantly, CH25H expression was significantly up‐regulated in both cell lines (Fig 1A). Similar results were obtained from infections by human parainfluenza virus type 3 (HPIV3) and respiratory syncytial virus (RSV) but not influenza A virus, whose NS1 protein could completely block interferon pathways (Fig 1A). In corroboration with these cell line‐based data, scRNA‐seq analysis of bronchoalveolar lavage fluids from healthy donors and COVID‐19‐infected patients revealed an up‐regulation of CH25H in macrophages and epithelial cells in COVID‐19‐infected patients compared to healthy donors (Figs 1B and EV1A; Liao et al, 2020). Another RNA‐seq analysis also showed robust induction of CH25H in PBMCs from COVID‐19‐infected patients relative to healthy donors (Fig EV1B; preprint: Daamen et al, 2020). [Figure: Cholesterol 25‐hydroxylase (CH25H) is induced by SARS‐CoV‐2 and restricts viral infection AIFNs and ISGs were induced by SARS‐CoV-2 infection in lung epithelial cell lines: Calu‐3 and A549‐ACE2 were infected with SARS‐CoV-2 at MOI = 2 for 24 h; A549 was challenged with IAV at MOI = 5 for 9 h; A549 was infected with HPIV3 and RSV at MOI = 2 for 24 h (Blanco‐Melo et al, 2020). Color key represents log2(fold change) relative to uninfected control cells. CH25H was highlighted by red asterisk.BExpression of CH25H in heathy donors and COVID‐19-infected patients. The box plot shows the expression of CH25H in macrophages of bronchoalveolar lavage fluids from four healthy donors, three moderate COVID‐19-infected patients and six severe COVID‐19-infected patients by scRNA‐seq analysis (Liao et al, 2020). *P < 0.05, ****P < 0.0001, by Student's